Neurocrine Biosciences (BSP:N1BI34) Short-Term Debt : R$833 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Neurocrine Biosciences Short-Term Debt?

Neurocrine Biosciences's Short-Term Debt for the quarter that ended in Dec. 2023 was R$833 Mil.

Neurocrine Biosciences's quarterly Short-Term Debt increased from Jun. 2023 (R$824 Mil) to Sep. 2023 (R$839 Mil) but then declined from Sep. 2023 (R$839 Mil) to Dec. 2023 (R$833 Mil).

Neurocrine Biosciences's annual Short-Term Debt increased from Dec. 2021 (R$0 Mil) to Dec. 2022 (R$889 Mil) but then declined from Dec. 2022 (R$889 Mil) to Dec. 2023 (R$833 Mil).

Neurocrine Biosciences Short-Term Debt Historical Data

The historical data trend for Neurocrine Biosciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Short-Term Debt Chart

Neurocrine Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

1,677.92

888.57

833.46

Neurocrine Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt	Get a 7-Day Free Trial															888.57	-	823.67	839.09	833.46

Neurocrine Biosciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Neurocrine Biosciences Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences (BSP:N1BI34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (BSP:N1BI34) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

NBIX:USA NB3:Germany

Address

12780 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.neurocrine.com

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences (BSP:N1BI34) Headlines

No Headlines